These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27747531)

  • 21. Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs.
    Bhati M; Bandyopadhyay S
    Clin Rheumatol; 2016 Aug; 35(8):1931-1935. PubMed ID: 27334114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.
    Fleischmann RM
    Arthritis Rheum; 2009 Nov; 60(11):3225-8. PubMed ID: 19877057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers.
    Pyrpasopoulou A; Douma S; Triantafyllou A; Simoulidou E; Samara M; Parapanisiou E; Aslanidis S
    Mol Diagn Ther; 2010 Feb; 14(1):43-8. PubMed ID: 20121289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.
    Keystone EC; Cohen SB; Emery P; Kremer JM; Dougados M; Loveless JE; Chung C; Wong P; Lehane PB; Tyrrell H
    J Rheumatol; 2012 Dec; 39(12):2238-46. PubMed ID: 23027887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-cell therapies in established rheumatoid arthritis.
    Leandro MJ; Becerra-Fernandez E
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful therapy of rheumatoid arthritis with rituximab: renewed interest in the role of B cells in the pathogenesis of rheumatoid arthritis.
    Kramm H; Hansen KE; Gowing E; Bridges A
    J Clin Rheumatol; 2004 Feb; 10(1):28-32. PubMed ID: 17043458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
    Fleischmann RM
    Semin Arthritis Rheum; 2009 Feb; 38(4):265-80. PubMed ID: 18336874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. To flare or not to flare: patients' and rheumatologists' perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis.
    Bertrand D; Deprez A; Doumen M; De Cock D; Pazmino S; Marchal A; Thelissen M; Joly J; De Meyst E; Neerinckx B; Westhovens R; Verschueren P
    Ther Adv Musculoskelet Dis; 2024; 16():1759720X241232268. PubMed ID: 38425577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methotrexate induced neurotoxicity in a patient with rheumatoid arthritis on rituximab therapy: a case-based review.
    Kougkas N; Dara A; Pagkopoulou E; Dimitriadou A; Papadimitriou E; Avdelidou E; Garyfallos A; Dimitroulas T
    Rheumatol Int; 2022 Oct; 42(10):1849-1854. PubMed ID: 35849191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.
    Walsh CA; Fearon U; FitzGerald O; Veale DJ; Bresnihan B
    Clin Exp Rheumatol; 2008; 26(4):656-8. PubMed ID: 18799100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Safety of rituximab in patients with rheumatoid arthritis].
    Morović-Vergles J
    Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.
    Hainsworth JD
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S12-6. PubMed ID: 15180892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
    Dass S; Vital EM; Emery P
    Expert Opin Pharmacother; 2006 Dec; 7(18):2559-70. PubMed ID: 17150009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].
    Hernández-Cruz B; García-Arias M; Ariza Ariza R; Martín Mola E
    Reumatol Clin; 2011; 7(5):314-22. PubMed ID: 21925447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis.
    Kim JW; Jung JY; Shin K; Suh CH; Kim HA
    Front Med (Lausanne); 2021; 8():765535. PubMed ID: 34778324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab for the treatment of rheumatoid arthritis.
    Schuna AA
    Pharmacotherapy; 2007 Dec; 27(12):1702-10. PubMed ID: 18041890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability and safety of rituximab (MabThera).
    Kimby E
    Cancer Treat Rev; 2005 Oct; 31(6):456-73. PubMed ID: 16054760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.